Bringing the NAMs Revolution to Women's Health
How New Approach Methodologies (NAMs) can shift drug discovery and bring powerful advancements in women’s health
Application Note: Human Endometrial Organoids as a New Approach Methodology (NAM) for Preclinical Cytotoxicity Testing in Women’s Reproductive Health
We present patient-derived endometrial organoids as a sensitive and scalable model for reproductive toxicity screening, aligning with FDA and NIH priorities for human-based NAMs.
Future of Biotech: Organoids
The FDA’s shift toward organoid-based and AI-powered drug testing marks a new era in biotech. Opal Therapeutics is leading in women’s health with our uterus-in-a-dish platform—using patient-derived uterine organoids to model diseases like endometriosis and fibroids with human-relevant precision.